Table 3. Multivariate Cox proportional hazards model analysis for TTF and OS in patients with wild-type non-small cell lung cancer.
| TTF | OS | ||||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | ||
| Age (< 70 vs. ≥ 70 years) | 0.87 | 0.61–1.26 | 0.47 | 0.77 | 0.51–1.18 | 0.24 | |
| Sex (female vs. male) | 0.80 | 0.53–1.21 | 0.29 | 0.93 | 0.58–1.47 | 0.75 | |
| Smoking† (no vs. yes) | 1.59 | 0.95–2.65 | 0.07 | 1.60 | 0.92–2.78 | 0.09 | |
| Histology (non-sq vs. sq) | 1.43 | 1.02–2.01 | 0.03 | 1.04 | 0.70–1.54 | 0.81 | |
| ECOG PS (0–1 vs. ≥2) | 1.89 | 1.36–2.64 | <0.01 | 1.97 | 1.36–2.86 | <0.01 | |
| NLR (<5 vs. ≥5) | 2.51 | 1.77–3.58 | <0.01 | 2.59 | 1.73–3.87 | <0.01 | |
| 1st line cytotoxic anticancer drugs (platinum-based doublet/monotherapy) | 1.52 | 0.96–2.38 | 0.06 | 2.00 | 1.25–3.21 | <0.01 | |
| ICI treatment (yes vs. no) | 2.36 | 1.55–3.61 | <0.01 | ||||
†, history of >10 pack years. TTF, time to treatment failure; OS, overall survival; HR, hazard ratio; CI, confidence interval; sq, squamous; ECOG PS, Eastern Cooperative Group performance status; NLR, neutrophil-to-lymphocyte ratio; ICI, immune checkpoint inhibitor.